To read the full story, subscribe or sign in.

After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work

Sep. 29, 2003

Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...